DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

Not Applicable

Completed

Conditions: Celiac Disease

Interventions: Dietary Supplement: Gluten

First Posted Date: 2018-01-24

Last Posted Date: 2022-05-24

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT03409796

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life

Terminated

Conditions: Colitis, Ulcerative
Crohn Disease
Inflammatory Bowel Diseases

First Posted Date: 2017-12-19

Last Posted Date: 2020-10-14

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT03378388

Locations: 🇫🇷
Centre Hospitalier Cote Basque, BAYONNE Cedex, France
🇫🇷
Ch de Blois, Blois Cedex, France
🇫🇷
Clinique du palais, Grasse, France

and more 10 locations

A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects

Phase 4

Completed

Conditions: Pandemic Influenza Prevention

Interventions: Biological: BLB-750 Vaccine (Qinghai RG strain)

First Posted Date: 2017-12-12

Last Posted Date: 2019-07-29

Lead Sponsor: Takeda

Target Recruit Count: 55

Registration Number: NCT03370289

Locations: 🇯🇵
Sekino Rinsho Yakuri Clinic, Toshima-ku, Tokyo, Japan

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Phase 3

Completed

Conditions: Dengue

Interventions: Biological: YF-17D
Biological: TDV
Drug: Placebo

First Posted Date: 2017-11-17

Last Posted Date: 2020-10-08

Lead Sponsor: Takeda

Target Recruit Count: 900

Registration Number: NCT03342898

Locations: 🇺🇸
Coastal Clinical Research Inc, Mobile, Alabama, United States
🇺🇸
Rapid Medical Research Inc, Cleveland, Ohio, United States
🇺🇸
Empire Clinical Research, Pomona, California, United States

and more 7 locations

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

Phase 1

Completed

Conditions: Virus, Zika
Healthy Participants
Zika Virus Disease
Flavivirus Infections

Interventions: Drug: Placebo
Biological: PIZV

First Posted Date: 2017-11-17

Last Posted Date: 2022-02-11

Lead Sponsor: Takeda

Target Recruit Count: 271

Registration Number: NCT03343626

Locations: 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇵🇷
Ponce Medical School Foundation, Santurce, Puerto Rico
🇵🇷
Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico

and more 6 locations

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

Phase 3

Completed

Conditions: Dengue

Interventions: Biological: Tetravalent Dengue Vaccine (TDV)
Biological: Placebo

First Posted Date: 2017-11-14

Last Posted Date: 2019-08-15

Lead Sponsor: Takeda

Target Recruit Count: 400

Registration Number: NCT03341637

Locations: 🇲🇽
Instituto Nacional de Pediatria (INP), Mexico City, Mexico
🇲🇽
Mexico Centre for Clinical Research, Mexico City, Mexico
🇲🇽
Centro de Atencion E Investigacion Medica (CAIMED) Mexico DF, Mexico City, Mexico

and more 2 locations

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2017-11-13

Last Posted Date: 2021-09-20

Lead Sponsor: Takeda

Target Recruit Count: 35

Registration Number: NCT03339219

Locations: 🇯🇵
Keio University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan
🇯🇵
Kyushu University Hospital, Fukuoka, Japan

and more 16 locations

Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Participants With Narcolepsy

Phase 1

Completed

Conditions: Healthy Participants and Patients With Narcolepsy

Interventions: Drug: TAK-925
Drug: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2021-03-30

Lead Sponsor: Takeda

Target Recruit Count: 58

Registration Number: NCT03332784

Locations: 🇯🇵
PS Clinic, Fukuoka, Japan
🇯🇵
Hakata Clinic, Fukuoka, Japan
🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan

A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants

Phase 1

Completed

Conditions: Crohn Disease
Colitis, Ulcerative

Interventions: Drug: Vedolizumab

First Posted Date: 2017-11-01

Last Posted Date: 2019-09-06

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT03329209

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes

Completed

Conditions: Classical Hodgkin Lymphoma
Relapsed or Refractory Classical Hodgkin Lymphoma

First Posted Date: 2017-10-31

Last Posted Date: 2021-06-25

Lead Sponsor: Takeda

Target Recruit Count: 1770

Registration Number: NCT03327571

Locations: 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy